-
Posted by
Two Blokes Jun 15 -
Filed in
Stock
-
5 views
Media Release COPENHAGEN, Denmark; June 15, 2025 Results from the EPCORE \u00ae NHL-2 trial show investigational treatment with epcoritamab in combination with rituximab, ifosfamide, carboplatin, and etoposide (R-ICE) led to an overall response rate (ORR) of 87 percent and a complete response (CR) rate of 65 percent in patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) Data further demonstrates the potential of epcoritamab in combination with salvage chemoimmunotherapy to increase the proportion of patients to qualify for Autologous Stem Cell Transplantation (ASCT) Data was presented during an oral session at the 30 th European Hematology Association (EHA) Congress Genmab A/S (Nasdaq: GMAB ) today a nnounced new results from the Phase 1b/2 EPCORE \u00ae NHL-2 trial Arm 10 ( NCT04663347 ), evaluating epcoritamab , a T-cell engaging bispecific antibody administered subcutaneously, in combination with rituximab, ifosfamide, carboplatin, and etoposide (R-ICE) in adult patients with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) who are eligible for autologous stem cell transplantation (ASCT). Results demonstrated an overall response rate (ORR) of 87 percent, a complete response (CR) rate of 65 percent and a partial response (PR) of 23 percent.
